Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for September...

Tue Oct 14, 2008 7:00am EDT

* Reuters is not responsible for the content in this press release.

Boston Scientific Announces Drug-Eluting Stent Market Share Estimates for
September and Third Quarter
TAXUS(R) Atom(TM) in more than 500 accounts Company opening new PROMUS(TM)

NATICK, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Boston Scientific
Corporation (NYSE: BSX) today announced estimated U.S. market shares for
September for its two drug-eluting stents (DES), based on preliminary data
from Millennium Research Group (MRG), a leading provider of strategic
information to the healthcare sector.
    Based on the MRG data, the Company estimates its share percentages of the
U.S. DES market for September as follows:
    -- Boston Scientific's PROMUS(TM) Everolimus-Eluting Coronary Stent
System: 25 percent
    -- Boston Scientific's TAXUS(R) Express2(TM) Paclitaxel-Eluting Coronary
Stent System: 19 percent
    The Company said the estimated aggregate U.S. market share for its two
drug-eluting stents for the third quarter was approximately 45 percent, based
on MRG data.  The Company reported the same aggregate U.S. market share for
the second quarter.
    TAXUS Atom update
    The Company said it has introduced its TAXUS(R) Express2(TM) Atom(TM)
Paclitaxel-Eluting Coronary Stent System to more than 500 accounts in the
United States.  The TAXUS Atom stent is the only 2.25 mm diameter drug-eluting
stent available in the United States.  It was approved by the U.S. Food and
Drug Administration (FDA) last month.  It provides a drug-eluting stent
treatment option for patients with small vessels for whom no DES was
previously available.  The Company said it is encouraged by the positive
reception among clinicians for the TAXUS Atom stent.  It said it believes the
TAXUS Atom stent is increasing both the use of drug-eluting stents and Boston
Scientific's share of the market.
    Opening new PROMUS accounts
    The Company announced it has: increased inventory supply orders for its
PROMUS stent system, received increased supply this month, solidified supply
to existing accounts, and has begun opening new PROMUS accounts.  The Company
said it has ordered sufficient additional PROMUS supply to continue opening
new accounts through the remainder of this year and into the beginning of next
year.  It added that while expanding into new accounts, it will continue to
supply existing accounts as well.
    "These recent developments bode well for ongoing leadership by Boston
Scientific in the drug-eluting stent market," said Jim Tobin, President and
Chief Executive Officer of Boston Scientific.  "With a market-leading
aggregate share of approximately 45 percent, our two-drug platform is offering
doctors excellent choices for their patients.  TAXUS Atom is filling an unmet
need in small vessel patients, one that could expand the drug-eluting stent
market substantially.  We have taken steps to improve our PROMUS inventory so
we can solidify supply to our existing accounts and simultaneously begin to
open new accounts.   In addition to these developments, we now have FDA
approval for our TAXUS(R) Liberte(R) Paclitaxel-Eluting Coronary Stent System,
a thinner-strut, second-generation TAXUS stent that we believe will provide
U.S. clinicians and their patients another safe, effective and even more
deliverable drug-eluting stent option.  We are also expecting FDA approval of
our next-generation Apex(TM) balloon catheter soon."
    Boston Scientific is a worldwide developer, manufacturer and marketer of
medical devices whose products are used in a broad range of interventional
medical specialties.  For more information, please visit:
    Cautionary Statement Regarding Forward-Looking Statements
    This press release contains forward-looking statements within the meaning
of Section 21E of the Securities Exchange Act of 1934.  Forward-looking
statements may be identified by words like "anticipate," "expect," "project,"
"believe," "plan," "estimate," "intend" and similar words.  These forward-
looking statements are based on our beliefs, assumptions and estimates using
information available to us at the time and are not intended to be guarantees
of future events or performance.  These forward-looking statements include,
among other things, statements regarding regulatory approvals, clinical
trials, product performance and competitive offerings.  If our underlying
assumptions turn out to be incorrect, or if certain risks or uncertainties
materialize, actual results could vary materially from the expectations and
projections expressed or implied by our forward-looking statements.  These
factors, in some cases, have affected and in the future (together with other
factors) could affect our ability to implement our business strategy and may
cause actual results to differ materially from those contemplated by the
statements expressed in this press release.  As a result, readers are
cautioned not to place undue reliance on any of our forward-looking
    Factors that may cause such differences include, among other things:
future economic, competitive, reimbursement and regulatory conditions; new
product introductions; demographic trends; intellectual property; litigation;
financial market conditions; and, future business decisions made by us and our
competitors.  All of these factors are difficult or impossible to predict
accurately and many of them are beyond our control.  For a further list and
description of these and other important risks and uncertainties that may
affect our future operations, see Part I, Item 1A - Risk Factors in our most
recent Annual Report on Form 10-K filed with the Securities and Exchange
Commission, which we may update in Part II, Item 1A - Risk Factors in
Quarterly Reports on Form 10-Q we have filed or will file thereafter.  We
disclaim any intention or obligation to publicly update or revise any forward-
looking statements to reflect any change in our expectations or in events,
conditions, or circumstances on which those expectations may be based, or that
may affect the likelihood that actual results will differ from those contained
in the forward-looking statements.  This cautionary statement is applicable to
all forward-looking statements contained in this document.

    CONTACT: Paul Donovan
             508-650-8541 (office)
             508-667-5165 (mobile)
             Media Relations
             Boston Scientific Corporation

             Larry Neumann
             508-650-8696 (office)
             Investor Relations
             Boston Scientific Corporation

SOURCE  Boston Scientific Corporation

Paul Donovan, Media Relations, +1-508-650-8541 (office), +1-508-667-5165
(mobile), or Larry Neumann, Investor Relations, +1-508-650-8696 (office), both
of Boston Scientific Corporation
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.